Membrane Transporters as Mediators of Cisplatin Effects and Side Effects

Giuliano Ciarimboli

doi:10.6064/2012/473829

journal article Open Access Jan 01, 2012

Membrane Transporters as Mediators of Cisplatin Effects and Side Effects

Giuliano Ciarimboli

Scientifica Vol. 2012 pp. 1-18 · Hindawi Limited

View at Publisher Save 10.6064/2012/473829

Abstract

Transporters are important mediators of specific cellular uptake and thus, not only for effects, but also for side effects, metabolism, and excretion of many drugs such as cisplatin. Cisplatin is a potent cytostatic drug, whose use is limited by its severe acute and chronic nephro-, oto-, and peripheral neurotoxicity. For this reason, other platinum derivatives, such as carboplatin and oxaliplatin, with less toxicity but still with antitumoral action have been developed. Several transporters, which are expressed on the cell membranes, have been associated with cisplatin transport across the plasma membrane and across the cell: the copper transporter 1 (Ctr1), the copper transporter 2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B, the organic cation transporter 2 (OCT2), and the multidrug extrusion transporter 1 (MATE1). Some of these transporters are also able to accept other platinum derivatives as substrate. Since membrane transporters display a specific tissue distribution, they can be important molecules that mediate the entry of platinum derivatives in target and also nontarget cells possibly mediating specific effects and side effects of the chemotherapeutic drug. This paper summarizes the literature on toxicities of cisplatin compared to that of carboplatin and oxaliplatin and the interaction of these platinum derivatives with membrane transporters.

Topics

No keywords indexed for this article. Browse by subject →

References

203

[1]

10.1038/nrd2438

[2]

10.1517/17425255.2011.547474

[3]

10.1080/00498250701867889

[4]

10.1086/508546

[5]

10.1016/j.bcp.2010.11.016

[6]

10.1016/j.drup.2010.12.002

[7]

Drug Resistance Updates (2012)

[8]

10.1073/pnas.072067999

[9]

10.1038/205698a0

[10]

Chemical Reviews (1999) 10.1021/cr980420v

[11]

10.1016/j.ctrv.2006.09.006

[12]

Toxicity of platinum compounds

Jörg Thomas Hartmann, Hans-Peter Lipp

Expert Opinion on Pharmacotherapy 10.1517/14656566.4.6.889

[13]

10.1016/s1040-8428(00)00070-6

[14]

Cellular processing of platinum anticancer drugs

Dong Wang, Stephen J. Lippard

Nature Reviews Drug Discovery 10.1038/nrd1691

[15]

10.1021/cr020010d

[16]

Toxicology Letters (1989)

[17]

Danish Medical Bulletin (1990)

[18]

Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies

N. Pabla, Z. Dong

Kidney International 10.1038/sj.ki.5002786

[19]

Cancer Chemotherapy and Pharmacology (1986) 10.1007/bf00253068

[20]

Cancer Research (1976)

[21]

Journal of Pharmacology and Experimental Therapeutics (1980) 10.1016/s0022-3565(25)32105-1

[22]

American Journal of Physiology (2004)

[23]

American Journal of Physiology (1996)

[24]

Cancer Chemotherapy and Pharmacology (1986)

[25]

Pharmacology and Toxicology (1992) 10.1111/j.1600-0773.1992.tb00445.x

[26]

Seminars in Oncology (2002) 10.1016/s0093-7754(02)90016-3

[27]

10.1016/j.ejca.2004.08.002

[28]

Cancer Treatment Reports (1982)

[29]

10.1038/sj.ki.5002434

[30]

10.1097/moo.0b013e3282eee452

[31]

10.1007/s00381-010-1300-1

[32]

Cancer Chemotherapy and Pharmacology (1990) 10.1007/bf02897206

[33]

10.1093/jnci/djn418

[34]

Cochrane Database of Systematic Reviews (2011)

[35]

NeuroToxicology (1999)

[36]

Cancer (1984) 10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9

[37]

Neurology (1984) 10.1212/wnl.34.7.934

[38]

Revista de Neurologia (1998) 10.33588/rn.27158.98106

[39]

10.1016/s0162-0134(99)00135-x

[40]

10.1007/s00280-009-1017-6

[41]

Acta Neurologica Scandinavica (1987) 10.1111/j.1600-0404.1987.tb03551.x

[42]

10.1093/brain/awl356

[43]

Neuropathology and Applied Neurobiology (1999)

[44]

Acta Neuropathologica (1992)

[45]

10.1023/a:1008231925889

[46]

10.1016/s0959-8049(01)00300-8

[47]

10.1006/toxs.1998.2558

[48]

10.1054/bjoc.2001.2024

[49]

Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss

SMF Jamieson, J Liu, B Connor et al.

Cancer Chemotherapy and Pharmacology 10.1007/s00280-004-0953-4

[50]

Acta Neuropathologica (1986) 10.1007/bf00688308

Showing 50 of 203 references

Metrics

43

Citations

203

References

Details

Published: Jan 01, 2012
Vol/Issue: 2012
Pages: 1-18
License: View

Authors

G

Giuliano Ciarimboli

Experimentelle Nephrologie, Medizinische Klinik D, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A14, 48149 Münster, Germany

Funding

Deutsche Krebshilfe Award: 108539

Cite This Article

Giuliano Ciarimboli (2012). Membrane Transporters as Mediators of Cisplatin Effects and Side Effects. Scientifica, 2012, 1-18. https://doi.org/10.6064/2012/473829

Membrane Transporters as Mediators of Cisplatin Effects and Side Effects

You May Also Like